ACT Brief: NIH Funding Reshaping Development Strategy, Business Decision Setting Execution Course, and Complex Modality Platform Gaps

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new video interview, Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, explains how declining NIH funding, late-stage pharma acquisition strategies, and global operating pressures are forcing sponsors to move faster and more capital-efficiently toward clinical inflection points. These three forces together are reshaping how biotech companies allocate resources and define development priorities.
• In a new Q&A, Elizabeth Walsh, founder of Walsh Clinical Advisory, discussed how execution strategy must begin at the business decision rather than study startup, since outsourcing tasks does not transfer accountability or ownership, which must always remain with the sponsor. Building genuine inspection readiness requires qualified people bridging scientific intent into operational reality and maintaining continuous active oversight rather than delegating through periodic review layers.
• In an article from Pharmaceutical Executive, Christian Olsen, VP of strategy at Dotmatics, described how legacy LIMS and ELN platforms designed for monoclonal antibodies are failing complex modalities like multispecific antibodies and antibody drug conjugates. When scientific reasoning is not captured as a data architecture element, judgment evaporates at each handoff and subsequent teams must essentially restart their work rather than building on established conclusions.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.